Hyperliquid Strategies Inc (PURR) Stock Price, Quote & News

Company Profile

Hyperliquid Strategies Inc. operates as a digital asset treasury company focused on the blockchain and cryptocurrency sector. The company provides investors exposure to the HYPE token through treasury management strategies, such as token accumulation, staking, and yield optimization within the Hyperliquid ecosystem. The company was incorporated in 2025 and is based in New York, New York.

Industry: Capital Markets

Sector: Financial Services

Phone: 212 883 4330

Website: www.hypestrat.xyz

Address:

477 Madison Avenue, 22nd Floor, New York, United States

CharlesLazewski381 Aug. 19 at 9:13 AM

$PURR $ACHR $KTA $CEG PURR remains highly speculative, Archer advances electric-air-taxi technology, KTA remains speculative, and Constellation Energy benefits from nuclear-power demand and data-center electricity needs. I'm watching liquidity, certification milestones, contracts, power demand, and nuclear capacity.

1 · Reply

DeanPresto849 Aug. 19 at 7:15 AM

1 · Reply

silentmax Aug. 19 at 1:41 AM

$PURR $HYPE.X Americans can trade Unitree on hyperliquid...on the down low of course.....

0 · Reply

Fnkychld Aug. 18 at 11:56 PM

$PURR keep adding to my position.

0 · Reply

Scalptrades101 Aug. 18 at 11:20 PM

$SPY $QQQ $PURR Timed the top perfect on that sweet pump and dump, looking better down here

0 · Reply

KornieAwareness7 Aug. 18 at 10:10 PM

$PURR $SOL.X $ETH.X $SECZ

2 · Reply

VannaBlack Aug. 18 at 8:07 PM

$QQQ $PURR oooofff 23 hour trading days, 5 days a week by December 6th. just in time for Christmas https://finance.yahoo.com/markets/stocks/articles/nasdaq-plans-nearly-23-hour-210330984.html

0 · Reply

VannaBlack Aug. 18 at 8:02 PM

$PURR $QQQ Nasdaq going to trade 23 hours a day 5 days a week

0 · Reply

24_7Markets Aug. 18 at 7:59 PM

$HYPE.X $PURR Big!!!!

0 · Reply

vu_jade Aug. 18 at 7:51 PM

$PURR $HYPE.X Time for breakout

0 · Reply

Hyperliquid Strategies Registration statement: Registration filing

Jul 8, 2026, 8:30 AM EDT - 5 weeks ago

Defiance Launches PUR: The First 2X Long PURR ETF

PUR

2026-07-01T19:50:11.000Z - 6 weeks ago

Hyperliquid Strategies management to meet with Oppenheimer

2026-06-29T20:20:21.000Z - 7 weeks ago

Hyperliquid Strategies to be added to Russell 3000, 2000, S&P Global BMI Indices

Jun 29, 2026, 4:15 PM EDT - 7 weeks ago

Hyperliquid Strategies Inc Added to the Russell 3000, Russell 2000 and S&P Global BMI Indices

Jun 25, 2026, 8:00 AM EDT - 7 weeks ago

Hyperliquid Strategies Registration statement: Registration filing

Jun 16, 2026, 9:00 AM EDT - 2 months ago

Hyperliquid Strategies Inc Relaunches Website with Expanded Analytics, HYPE Tokenomics and Insights Sections

Jun 16, 2026, 8:00 AM EDT - 2 months ago

Hyperliquid Strategies Registration statement: Registration filing

Jun 4, 2026, 5:46 PM EDT - 2 months ago

Hyperliquid Strategies CEO on why he thinks banks are undervaluing SpaceX's IPO

SPCX

May 22, 2026, 8:00 AM EDT - 3 months ago

Hyperliquid Strategies Registration statement: Registration filing

2026-05-22T10:05:07.000Z - 3 months ago

Hyperliquid Strategies files to sell 35.16M shares of common stock for holders

2026-05-11T12:53:34.000Z - 3 months ago

Hyperliquid Strategies price target raised to $8 from $6 at Cantor Fitzgerald

May 7, 2026, 5:00 PM EDT - 3 months ago

Hyperliquid Strategies Earnings Call Transcript: Q3 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

Hyperliquid Strategies Slides: Q3 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

Hyperliquid Strategies Quarterly report: Q3 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

Hyperliquid Strategies Earnings release: Q3 2026

2026-05-07T20:47:48.000Z - 3 months ago

Hyperliquid Strategies, Unit Labs announce validator on Hyperliquid

May 7, 2026, 4:15 PM EDT - 3 months ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended March 31, 2026

May 7, 2026, 4:15 PM EDT - 3 months ago

Hyperliquid Strategies and Unit Labs Announce Validator on Hyperliquid

Apr 28, 2026, 4:15 PM EDT - 4 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Quarter Ended March 31, 2026

2026-04-24T12:14:26.000Z - 4 months ago

Hyperliquid Strategies initiated with a Buy at Maxim

2026-04-24T12:06:12.000Z - 4 months ago

Hyperliquid Strategies initiated with a Buy at Maxim

Mar 24, 2026, 4:15 PM EDT - 5 months ago

Hyperliquid Strategies Inc. Announces Milestone with Launch of Options Trading on PURR Common Stock

Feb 16, 2026, 7:00 AM EST - 6 months ago

Hyperliquid Strategies Slides: Corporate presentation

Feb 11, 2026, 8:00 AM EST - 6 months ago

Hyperliquid Strategies Earnings Call Transcript: Q2 2026

Feb 11, 2026, 8:00 AM EST - 6 months ago

Hyperliquid Strategies Quarterly report: Q2 2026

Feb 11, 2026, 8:00 AM EST - 6 months ago

Hyperliquid Strategies Earnings release: Q2 2026

Feb 11, 2026, 8:00 AM EST - 6 months ago

Hyperliquid Strategies Slides: Q2 2026

Feb 11, 2026, 6:45 AM EST - 6 months ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended December 31, 2025

Feb 5, 2026, 4:15 PM EST - 6 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended December 31, 2025

Dec 8, 2025, 9:20 AM EST - 9 months ago

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Dec 3, 2025, 5:45 PM EST - 9 months ago

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Dec 2, 2025, 4:30 PM EST - 9 months ago

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Nov 18, 2025, 9:00 AM EST - 9 months ago

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Nov 12, 2025, 7:00 AM EST - 9 months ago

Hyperliquid Strategies Slides: Investor presentation

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Hyperliquid Strategies Registration statement: Registration Filing

Oct 15, 2025, 10:03 AM EDT - 10 months ago

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sep 19, 2025, 9:00 AM EDT - 11 months ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025, 9:15 AM EDT - 1 year ago

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 4, 2025, 8:40 AM EDT - 1 year ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025, 6:00 AM EDT - 1 year ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 1, 2025, 9:00 AM EDT - 1 year ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Apr 4, 2025, 9:00 AM EDT - 1 year ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 1, 2025, 4:15 PM EDT - 1 year ago

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Mar 26, 2025, 9:05 AM EDT - 1 year ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 19, 2025, 8:50 AM EDT - 1 year ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 11, 2025, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 19, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 18, 2025, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 13, 2025, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Jan 28, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 22, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 21, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Dec 23, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 17, 2024, 8:50 AM EST - 1 year ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 9, 2024, 3:42 PM EST - 1 year ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 8:45 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 4, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Nov 12, 2024, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 6, 2024, 1:20 PM EST - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 9, 2024, 8:45 AM EDT - 2 years ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 4, 2024, 8:30 AM EDT - 2 years ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sep 30, 2024, 9:00 AM EDT - 2 years ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

CharlesLazewski381 Aug. 19 at 9:13 AM

1 · Reply

DeanPresto849 Aug. 19 at 7:15 AM

1 · Reply

silentmax Aug. 19 at 1:41 AM

$PURR $HYPE.X Americans can trade Unitree on hyperliquid...on the down low of course.....

0 · Reply

Fnkychld Aug. 18 at 11:56 PM

$PURR keep adding to my position.

0 · Reply

Scalptrades101 Aug. 18 at 11:20 PM

$SPY $QQQ $PURR Timed the top perfect on that sweet pump and dump, looking better down here

0 · Reply

KornieAwareness7 Aug. 18 at 10:10 PM

$PURR $SOL.X $ETH.X $SECZ

2 · Reply

VannaBlack Aug. 18 at 8:07 PM

$QQQ $PURR oooofff 23 hour trading days, 5 days a week by December 6th. just in time for Christmas https://finance.yahoo.com/markets/stocks/articles/nasdaq-plans-nearly-23-hour-210330984.html

0 · Reply

VannaBlack Aug. 18 at 8:02 PM

$PURR $QQQ Nasdaq going to trade 23 hours a day 5 days a week

0 · Reply

24_7Markets Aug. 18 at 7:59 PM

$HYPE.X $PURR Big!!!!

0 · Reply

vu_jade Aug. 18 at 7:51 PM

$PURR $HYPE.X Time for breakout

0 · Reply

VannaBlack Aug. 18 at 4:20 PM

$PURR interesting option trades in the December contracts. Selling (maybe buying but bad trade imo) $7 straddles for $3+ premium. It weuld have to move against you by a significant amount either direction after earnings& IV crush eat into that premium. Liquidity ncreasingin options for $PURR. Bullish 1. still dominates the perp trade 2. Great platform that allows others to build products on top of it 3. 24/7 trading scared CBOE into offering exended hours trading for certain options 4. CEX/DEX hybrid platform can transact 200,000 orders in under a second 5. proved its value with ipos, oil and Friday night news dumps now are priced in by Monday and futures open more and more at the Hyoerliquid perp price. Bearish 1. Due to 50/50 splits on fees with apps like MetaMask and Phantom, fee volume has been cut in half this year, meaning lower buybackls. 2. Trump Jr. is on the board of polymarket and an advisor to Kalshi 3. No US access YET but progress

0 · Reply

VannaBlack Aug. 18 at 2:42 PM

$PURR $HYPE.X The moment I relaized I was right. Book runners for $GS using Hyperliquid perp pricing.It was way off but the sheer volume mad it difficult to gauge actual sentiment. $SPCX dumped an inssane amount of shares on retail.. All other pre-ipo perps have been within a few percentage of them opening.

0 · Reply

VannaBlack Aug. 18 at 2:25 PM

$HYPE.X $PURR I think earnings might disappoint due to the 50/50 fee splits they have with MetaMask and others but it’s facing a lot of competition but a better exchange w/ more builders w/ low fees will win every time.It’s basically new highs in TVL but fees are cut in half. Still positive but I really hope earnings happen today after market close. The delay has me worried although I can see in real time what is occuring. https://defillama.com/protocol/hyperliquid https://app.coinmarketman.com/hypertracker/perps https://hypestrat.xyz/dashboard If you hold $PURR or $HYPE.X these are my 3 favorite tools to see what is going on. Even if you don’t, if you trade $CL_F futures or Brent this exchange should always be on your watchlist especially over weekends.

0 · Reply

howardlindzon Aug. 18 at 1:21 PM

$PURR $HYPE.X Introduces pre IPO perps https://x.com/HyperliquidPC/status/2089684060989727182 I love the smell of the degenerate economy In the morning...

1 · Reply

BenitoFlores653 Aug. 18 at 12:00 PM

$VIST $PLTR $SNDU $PURR Vista Energy remains leveraged to oil and gas prices, Palantir benefits from government and enterprise AI adoption, SNDU remains speculative, and PURR remains highly speculative. I'm watching energy prices, AI contracts, funding, and liquidity.

0 · Reply

TerranceMares253 Aug. 18 at 11:40 AM

$RYCEY $ASST $BRK.B $PURR Rolls-Royce benefits from aerospace-engine demand and aftermarket services, ASST remains speculative, Berkshire Hathaway provides diversified capital allocation, and PURR remains highly speculative. I'm watching engine deliveries, contracts, capital allocation, and liquidity.

1 · Reply